TRP
Pharmaceuticals, Biotechnology & Life Sciences
Tissue Repair
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 2 Dec 2025
- Reported shorts
- 7.7K
- Shares on issue
- 60.465M
Tissue Repair (TRP) company profile
Profile, insiders and operations
Company
AI-generated research profile of Tissue Repair
pharmaceuticals
biotechnology
wound healing
clinical stage
ASX
Tissue Repair is a clinical-stage biopharmaceutical company focused on developing advanced therapies for chronic and acute wound healing, targeting both medical and aesthetic applications. Their core technology, Glucoprime, is a yeast-derived beta-glucan with immunomodulatory effects that support tissue regeneration. The company launched TR Pro+ in June 2023 for aesthetic procedures and minor medical treatments and has initiated Phase 3 clinical trials for venous leg ulcers.
TRP intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required